Off-Target Effects with Matt Gline
Episodes
Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term
23 Apr 2026
Contributed by Lukas
He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company'...
Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top
09 Apr 2026
Contributed by Lukas
Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today...
Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year
30 Jun 2025
Contributed by Lukas
Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses...
Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries
08 May 2025
Contributed by Lukas
Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of...
Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector
10 Apr 2025
Contributed by Lukas
One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and wh...
Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it
17 Feb 2025
Contributed by Lukas
For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and knowledge of investi...